Professor Yunfeng Lin of Yunhai Bio Invited to Attend the "Sci-Tech Tianfu · Intelligence Converges in Chengdu" Technology Achievements Docking Event

On November 18, 2024, the "Sci-Tech Tianfu – Intelligence Converges in Chengdu" technology achievements docking event was held at the Tianfu International Convention Center. Professor Yunfeng Lin, Chief Scientist of Yunhai Bio, was invited to participate and showcased the project "Framework Nucleic Acid Drug Development" through a roadshow presentation.

The event attracted experts and scholars from major universities, corporate representatives, and industry elites. Several specialized matchmaking sessions were organized, focusing on industries such as advanced manufacturing, healthcare, and new materials. Over a hundred high-value technological achievements were unveiled, facilitating precise connections between technology needs and R&D projects. This initiative promoted efficient integration of scientific resources, market demands, and capital support, accelerating the industrialization of innovative achievements.

Professor Yunfeng Lin's team has been committed to the development of a framework nucleic acid drug system and its clinical applications in disease treatment. Extensive prior research has demonstrated the excellent potential of the tetrahedral framework nucleic acid (tFNA) delivery system in fields such as tissue regeneration, targeted therapy, molecular transport, gene delivery, and drug delivery.

In an interview with the media, Professor Yunfeng Lin stated:"Currently, nucleic acid drugs are a major hotspot in global new drug development. After more than a decade of research, our team has developed a technology that uses spatial folding to achieve efficient and non-toxic delivery of nucleic acids. This innovation could become the third major category of delivery technology after viral and liposomal methods, proposing a Chinese solution and amplifying China's voice in the international nucleic acid delivery arena." Professor Lin emphasized, "A sufficiently good technology will surely gain recognition from both the market and investors."

Guided by its vision to become a global leader in the framework nucleic acid industry, Yunhai Bio remains dedicated to establishing a world-class "Chinese solution" for drug and gene delivery. The company provides cutting-edge technological support for fields such as immune modulation, tissue regeneration, and targeted therapy, driving the industrialization of framework nucleic acids and exploring new directions in life sciences.